Abstract: A method for the synthesis of 2',3'-dideoxycytidine comprising a novel procedure of bromoacetylating cytidine to yield novel intermediates which are subsequently reduced and hydrogenated by novel procedures to yield 2',3'-dideoxycytidine.

Abstract: Metal chelate resins whose complexed nitrilotriacetic acid residues are bound to a carrier matrix via a spacer and which are suitable for metal chelate chromatography of proteins, especially those which contain neighboring histidines.

Abstract: The invention is concerned with novel isoquinoline derivatives of the formula ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, aryl-lower alkyl or aryl-lower alkoxy andR.sup.2 is phenyl or substituted phenyl.These novel isoquinoline derivatives are valuable intermediates in the manufacture of morphinan derivatives.

Abstract: Novel methyl carbinol derivatives of Vitamin E and a method for their manufacture.

Abstract: A-B-C wherein A and C are each independently 2',3' dideoxynucleosides and B is a linking group; and a method of treating or preventing a retroviral injection in a subject by administering the compounds of the invention.

Abstract: Compounds of the formula ##STR1## wherein the various substituents are defined hereinbelow and the pharmaceutically acceptable acid addition salts thereof, possess pharmacological properties. In particular, they possess antibacterial, antimycotic, protozoacidal and/or anthelmintic properties.

Abstract: Compounds of the general formula ##STR1## wherein R represents an ether protecting group and R.sup.1 is a group of (a)-(d) useful as intermediates.

Abstract: A method for the production of substantially 100% pure N.alpha.-urethane protected amino acids is disclosed. This method eliminates the formation of di-peptide and tri-peptide contaminants. Reaction of blocking reagents at the carboxylate site on a protected peptide is prevented by the application of labile amino acid esters. Subsequent removal of the ester yields, in ultra-high purity, the N.alpha.-protected amino acid. The substantially 100% pure N.alpha.-urethane protected amino acid are also disclosed.

Abstract: This invention relates to the microbial production, via recombinant DNA technology, of new human leukocyte interferons, Le IF-K and Le IF-L for use in the treatment of viral and neoplastic diseases, and to the means and end products of such production.

Abstract: Cyclic peptides with appetite regulating activity.

Abstract: This invention relates to the microbial production, via recombinant DNA technology, of new human leukocyte interferons, Le IF-K and Le IF-L for use in the treatment of viral and neoplastic diseases, and to the means and end products of such production.

Abstract: A method for measuring chloride ion concentration in a sample of body fluid, e.g., serum or plasma is described in which a sample blank is made in the same cuvette after the test measurement has been made.

Abstract: Benzodiazepine derivatives useful in immunoassays for benzodiazepines.

Abstract: Compounds of the general formula ##STR1## wherein R represents an ether protecting group and R.sup.3 is a group of (f)-(i) useful as intermediates.

Abstract: The invention is concerned with novel weed control compositions which contain herbicidally-active compounds of the formula ##STR1## wherein ring A, R.sup.1, R.sup.2, R.sup.3, Y and Z are as hereinafter set forth, and the use of these compounds and compositions for the control of weeds. The invention is also concerned with novel compounds of formula I as well as their preparation.

Abstract: Polypeptides corresponding to growth hormone releasing factor in which methionine at position 27 has been replaced by a leucine residue retain full growth hormone releasing activity. In the case of the full length (44-amino acid) polypepitide, the leucine analog has full biological activity in the free acid form, unlike the natural growth releasing factor which requires carboxy terminal amidation for full biological activity.

Abstract: Th preparation of a double-stranded polydeoxy ribonucleotide having cohesive termini each comprising one strand of a double-strand restriction endonuclease recognition site and, between the termini, a structural gene coating for the expression of recombinant growth hormone releasing factor, at least a majority of the codons and the coding strand of said gene being codons preferred for the expression of microbial genomes; a method of producing such DNA a recombinant microbial cloning vehicle comprising such DNA and the novel methods of producing said peptide are described.

Abstract: A new biological polypeptide hormone has been isolated from mammalian thymus and has been given the designation prothymosin alpha. This peptide contains approximately 107 to 113 amino acid residues depending on species and is distinguished by having the thymosin alpha.sub.1 sequence at its amino-terminus. Prothymosin alpha appears to represent the native polypeptide from which thymosin alpha.sub.1, thymosin alpha.sub.11 and other fragments are generated during the isolation of thymosin fraction 5. Prothymosin alpha is one of several peptides isolated from the thymic tissue which participate in the regulation, differentiation and function of thymic dependent lymphocytes (T cells). The new peptide appears to be more potent on a weight basis than thymosin alpha.sub.1 in the protection of subject animals against opportunistic infections.

Abstract: A method for determining total digoxin levels in a biological fluid sample containing digoxin-protein complex which method comprises disrupting the digoxin-protein complex by treating said sample solution with an effective amount of a dissociation agent selected from one or more members of the group consisting of a C.sub.3 -C.sub.26 saturated or unsaturated fatty acid, a C.sub.2-7 lower alkanol, quinidine and .alpha.-tocopherol so as to release the bound digoxin from serum protein, passing the treated sample solution through a centrifugal ultrafilter so as to selectively pass digoxin containing sample solution through said filter and retaining said serum proteins and determining the digoxin contents in said sample solution in a fluorescence polarization assay. A kit for carrying out the method is provided.

Abstract: Parathymyosin alpha is a novel peptide isolated from mammalian thymus and contains approximately 105 amino acid residues. It bears a high degree of homology to prothymosin alpha both in sequence and amino acid composition. Parathymosin alpha acts as a blocker or modulator or prothymosin alpha activity.